Plasma levels of bone Gla-.protein reflect bone formation in patients on chronic maintenance dialysis

Size: px
Start display at page:

Download "Plasma levels of bone Gla-.protein reflect bone formation in patients on chronic maintenance dialysis"

Transcription

1 Kidney International, Vol 26 (1984), pp Plasma levels of bone Gla-protein reflect bone formation in patients on chronic maintenance dialysis HARTMUT H MALLUCHE, MARIE-CLAUDE FAUGERE, PAOLO FANTI, and PAUL A PRICE Division of Nephrology, Bone and Mineral Metabolism, Department of Medicine, University of Kentucky, Lexington, Kentucky, and Department of Biology, University of Californi an Diego, California Plasma levels of bone Gla-protein reflect bone formation in patients on chronic maintenance dialysis Predictive value of plasma levels of bone Gla-protein (BGP) for bone histology was evaluated in 3 chronically dialyzed patients All patients underwent bone biopsies and serum biochemical parameters, including BUP, parathyroid hormone, and alkaline phosphatase; calcium and phosphate were measured at the time of biopsy Bone histology showed renal osteodystrophy with low bone turnover and osteomalacia (LT-ROD) in 13 patients, and renal osteodystrophy with high bone turnover and prevailing hyperparathyroid bone disease (HT-ROD) in 17 patients Values for BGP were above normal in LT-ROD ( vs 68 2 ng/ml) and extremely elevated in HT-ROD ( ng/ml) imilar differences were not found with the other serum biochemical parameters, even though BGP correlated with parathyroid hormone (r = 64) and alkaline phosphatase (r = 85) There were significant correlations between BGP and cellular and non-cellular parameters of bone formation (r = 73 to 91) Weaker or no correlations were found between BGP and histologic parameters of bone, reflecting mainly mineralization or resorption These correlations and the finding of significant differences in plasma BGP between LT-ROD and HT-ROD indicate that plasma levels of BGP reflect bone formation in uremia and predict underlying bone histology Les taux plasmatiques de Ia Gal-proteine osseuse reflètent Ia formation osseuse chez les malades en dialyse chronique La valeur des taux plasmatiques de Ia Gla-protcine osseuse pour Ia prediction de l'histologie osseuse a été ëvaluée chez 3 hemodialyzes chroniques Une biopsie osseuse a été pratiquée chez tous les malades et les prélèvements sanguins pour Ia mesure de Ia BGP, parathormone, alcaline phosphatase, calcium et phosphore ont été effectucs au moment de Ia biopsie L'histologie osseuse a révclé une ostéodystrophie rénale a faible niveau de remodelage (LT-ROD) chez 13 malades et une ostéodystrophie renal a haut niveau de remodelage avec hyperparathyroidisme (HT-ROD) chez 17 malades Les taux de BGP étaient au dessus de la normale chez les malades avec LT-ROD ( vs 68 2ng/ml) et extrcmement Clevés chez les malades avec HT-ROD ( ng/ml) Aucune difference entre les deux groupes n'a été retrouvce avec Ia parathormone ou alcaline phosphatase hien que BGP soit correlée avec Ia parathormone (r = 64) et Ia phosphatase alcaline (r = 85) Des correlations significatives ont etc établies entre Ia BGP et les paramctres cellulaires et non cellulaires de Ia formation osseuse (r 73 a 91) Des correlations plus faibles ou une absence de correlation ont etc trouvces entre BGP et les paramètres histologiques osseux de La minéralisation et de Ia resorption Ces correlations et Ia presence de differences significatives des taux plasmatiques de la BGP entre LT-ROD et HT-ROD indiquent que Ia BGP plasmatique refictent Ia formation osseuse chez les malades urémiques et predisent les anomalies histologiques osseuses reflects its content of three residues of the vitamin K-dependent amino acid, y-carboxyglutamic acid (GLA) BGP in plasma has the same apparent molecular weight as the pure bone GLAprotein and studies indicate that the plasma protein is probably the intact bone protein [31 With the availability of a radioimmunoassay for detection of BGP in plasma [3], it became possible to study BGP levels in various pathologic situations [4 7] Because bone and kidney may affect blood concentrations of BGP [8, 9], patients without kidney function allowed us to study the contribution of bone to blood levels of BGP rrelations between BGP and other serum biochemical parameters as well as histomorphometric parameters of bone in these patients might help us understand the role of BGP in bone metabolism and/or its value for predicting underlying bone histology In the present study we measured plasma BGP levels and other serum biochemical parameters in patients on chronic maintenance dialysis and evaluated the relationship between plasma BGP and quantitative static and dynamic parameters of bone structure, bone formation and resorption In addition, we studied the relative values of plasma BGP, serum levels of alkaline phosphatase, and parathyroid hormone (PTH) for the prediction of histologic changes in patients with uremic osteodystrophy Methods Patients Thirty consecutive patients who were scheduled for diagnostic bone biopsies were enrolled in the study There were 18 male patients and 12 female patients with a mean age of years (range, 13 to 72 years) All patients were on chronic maintenance dialysis Twenty-six of them were on hemodialysis and four on chronic ambulatory peritoneal dialysis Informed consent was obtained from all patients before the study The duration of dialytic therapy was months (range, 2 to 18 months) All patients were anuric None of the patients were parathyroidectomized or nephrectomized and none of them had been immobilized No other medical problems such as liver cirrhosis, diabetes mellitus, or malabsorption were known to exist All patients had normal outdoor activities and were on Bone Gla-protein (BGP), also referred to as 'osteocalcin," represents one of the most abundant non-collagenous bone proteins [1, 2] It has a molecular weight of 58 and the name Received for publication February 3, 1984, and in revised form June 7, by the International ociety of Nephrology 869

2 87 Malluche ci a! Table I tatic and dynamic quantitative parameters of bone structure, bone formation, and bone resorption in 3 dialyzed uremic patients" Parameters of bone structure Bone mass, % Lamellar osteoid volume, mm3/cm3 Woven osteoid volume, mm3icm Parameters of bone formation and resorption Lamellar osteoid surface, % Woven osteoid surface, % Thickness of lamellar osteoid, pm Bone-osteoblast interface, % Peritrabecular fibrosis, % Bone-osteoclast interface, % Parameters of bone dynamics Mineral apposition rate, pm/day Labelled osteoid seams, % Mineralization lag time, days LT-ROD 181 1W' HT-ROD Normal ntrols 25 39" l Abbreviations: LT-ROD, renal osteodystrophy with low bone turnover and osteomalacia; HT-ROD, renal osteodystrophy with high bone turnover and hyperparathyroid bone disease "Values are given as mean E b Normal values obtained from 84 normal American subjects [12]; values are given as mean D Normal values for dynamic parameters were obtained from 28 normal American subjects an unrestricted diet except for potassium and fluids The hemodialyzed patients were dialyzed three times weekly, 5 hr each, using the hollow fiber dialyzer (rdis Dow rp, Miami, Florida) with 15 m2 surface and dialysis machines (model AK1O, Travenol Laboratories, Inc, Morton Grove, Illinois) The dialysate contained 35 meq calcium and 2 meq magnesium No concurrent therapy was given with the exception of routine dialysis support medications including folic acid, iron, vitamin B6, phosphate binders, and multivitamins Bone biopsies Biopsy specimens were taken from the anterior iliac crest using an electric drill [11 Tetracycline hydrochloride was given (Tetracyn, 5 mg po bid) on day 19 and 2 before the biopsies, The drug was stopped for the following 12 days, and subsequently, demeclocycline hydrochloride (Declomycin 3 mg po bid) was given for 4 days Bone biopsy specimens were obtained 4 days thereafter Bone histology and histomorphometry Bone specimens were fixed in ethanol for 24 hr, dehydrated, and embedded in methylmethacrylate Undecalcified sections of 3- and 7- thickness were prepared using a microtome (Model 114, Jung, Heidelberg, Germany) The sections were stained with the modified Goidner's trichrome stain [111, which permits discrimination of calcified bone from osteoid and gives excellent cellular details [121, even-micron thick unstained sections were prepared for phase-contrast and fluorescence microscopy In addition, all slides were stained with a specific histochemical stain for detection of aluminum in bone [131 The slides were read without knowledge of clinical or biochemical information All sections were analyzed quantitatively for static and dynamic parameters of bone structure, bone formation, and resorption using the Osteoplan (Carl Zeiss, Thornwood, New York) according to Malluche et al [141 A minimum of 5 optical fields were evaluated at a magnification of x 2 using an objective with 4 numerical aperture Radioimmunoassay for BGP in plasma and dialysate At time of bone biopsies, blood samples were taken from all 3 patients for determination of plasma concentrations of BGP BGP was measured without knowledge of bone histology in triplicate using a radioimmunoassay with rabbit antibody directed against calf BGP [31 The antibody crossreacts with purified human BGP but not with BGP from rat or rabbit bone tudies with peptides of known structure derived from enzymatic digestion of BGP indicate that the rabbit antibody recognizes the COOH-terminal region of the 49-residue calf bone protein All determinations were done with four different dilutions (1, 1, 1, and 1 jd) to ascertain agreement between different dilutions and to assure that results were on scale The detection limit of the assay is 1 ng, the intraassay variation is less than 1%, and the intcrassay variation is less than 15% [3] To determine the effect of dialysis on plasma BGP levels, we measured plasma BGP in 6 of the 3 patients at the beginning and the end of a dialysis without ultrafiltration In addition, blood samples were obtained before and after passage through the dialyzer, that is, from arterial and venous sites, and dialysate samples were taken from the outflow of the dialyzer To determine day-to-day variations in plasma BGP levels of patients on chronic maintenance dialysis, we followed prospectively plasma BGP levels in these six patients For this purpose, blood was drawn at least once monthly before and after dialysis for 7 to 9 months Duration and schedule of dialysis were not changed during this time Biochemical measurements erum PTH levels were measured using a sensitive N-terminal parathyroid hormone radioimmunoassay which measures intact PTH (anti-human 1 34 PTH, courtesy of Dr David Endres, Nichols Laboratory, an Juan Capistrano, California) [15] erum concentrations of calcium were measured by atomic absorption spectrophotometry (Perkin-Elmer Model 5, Norwalk, nnecticut) erum phosphate, alkaline phosphatase, and creatinine were measured with an autoanalyzer (model MA 12, Technicon, Tarrytown, New York) tatistical analysis Linear regression analysis, multiple regression model analysis, and correlations were calculated between plasma BGP levels, PTH, alkaline phosphatase, and

3 Plasma BGP levels reflect bone formation 871 Table 2 erum biochemical parameters in 3 dialyzed uremic patients with various types of uremic bone disease' LT-ROD HT-ROD Normal Range CmEq/iiter 47± P, mg/dl Creatinine, mgldi AP, IU ipth, pg/mi BGP, ng/,nl Abbreviations: LT-ROD, Renal osteodystrophy with low bone turnover and osteomalacia; HT-ROD, Renal osteodystrophy with high bone turnover and hyperparathyroid bone disease a Values are given as mean EM 2 Table 3 rrelations (r-values) between histomorphometric parameters of bone and bone Gla-protein (BGP), alkaline phosphatase (AP), and parathyroid hormone (PTH) BGP AP PTH Parameters of bone structure Bone mass Lamellar osteoid volume Woven osteoid volume 73b 69a 62a Parameters of bone formation and resorption Lamellar osteoid surface 6 56 Woven osteoid surface 84" 58a 72b Bone-osteoblast interface 77b 66a 72b Osteoblastic index 78" 68a 73b Peritrabecular fibrosis 91" 76" 84b Bone-osteoclast interface 62a 63a 56a Osteoclastic index ofi b Parameters of bone dynamics Mineral apposition rate 91" 72" 92" Labelled osteoid seams k' Mineralization lag time a p <1 b p <1 15 E '1) - 1 C" E ) C" 5 LT-ROD HT-ROD 1 Plasma levels of bone Gla-protein in patients on chronic Fig maintenance dialysis with low bone turnover and osteomalacia (LT- ROD) and with high bone turnover and hyperparathyroid bone disease (HT-ROD) static and dynamic parameters of bone formation and resorption rrelations were calculated with correction for repetitive sampling Differences in serum biochemical parameters between the two histologic groups of uremic bone disease (see below) were calculated using the Mann-Whitney Rank um test for nonparametric differences All computations were done using the Proc-Gim-In statistical analysis system #979 [16] Results Bone histology Thirteen patients were found to have renal osteodystrophy with low bone turnover and osteomalacia (LT- ROD) The other 17 patients had renal osteodystrophy with high bone turnover and hyperparathyroid bone disease (HT- ROD) Histomorphometric data in these patients are shown in Table 1 Renal osteodystrophy with low bone turnover and osteomalacia was histologically characterized by accumulation of lamellar osteoid, low or normal number of osteoblasts and osteoclasts per unit trabecular surface, low fraction of actively mineralizing (doubly labelled) osteoid seams, decreased mineral apposition rate and prolonged mineralization lag time (Table 1) tainable bone aluminum was seen in 39% of these patients The fraction of bone osteoid interface exhibiting stainable bone aluminum ranged from 62 to 1% The histologic features of renal osteodystrophy with high bone turnover and hyperparathyroid bone disease were high normal or elevated cancelbus bone mass, accumulation of osteoid of abnormal, irregular "woven" collagen structure, abundance of osteoclasts and osteoblasts, and peritrabecular fibrosis The fraction of actively mineralizing osteoid seams was below normal, yet higher than in patients with LT-ROD The mineral apposition rate was high normal or elevated and mineralization lag time was normal tainable bone aluminum was seen in one of these patients with 12% of the osteoid-bone interface exhibiting stainable bone aluminum erum biochemistry There were no significant differences between serum calcium levels of patients with LT-ROD and HT-ROD (Table 2) erum phosphate levels were elevated in both groups, but there was no difference between LT-ROD and HT-ROD erum alkaline phosphatase levels were at the upper normal range in patients with LT-ROD and clearly elevated in patients with HT-ROD erum parathyroid hormone levels were elevated in both groups of patients, and patients with HT-ROD had significantly higher circulating levels of PTH, Plasma BGP Plasma BGP levels were abnormal in all patients Patients with HT-ROD had significantly higher plasma levels of BGP than patients with LT-ROD and there was no overlap in plasma BGP between the two groups (Fig 1) The highest plasma level of BGP in LT-ROD was 121 ng/ml, and the lowest value of plasma BGP in HT-ROD was 278 ng/ml (normal,

4 872 Malluche et al 8 A 6 B 'I) U, a' E (I) y = Iog(BGP) = 86 U, y = BGP 25 x 1-6 (BGP)' r = 84 I I I I I I I I Plasma levels of BGP, log Plasma levels of BGP, ng/ml rrelation between plasma levels of' bone Gin-protein and surface of lamellar osteoid in patients with low bone turnoverand Fig 2 A otleo,naiacia () and with high bone turnover and hyperparalhvroid bone disease ( ) B rrelation between plasma levels of bone Gin-protein and surface of woven osteojd in patients with low hone turnover and osteomcjlacia () and with high bone turnover and hvperparathvroid bone disease ( ) I 68 2 nglml) Plasma BGP levels measured in six patients at the beginning of a dialytic therapy were not different before and after passage through the dialyzer ( vs ng/ml) and no significant changes were found at the beginning and the end of a dialysis ( vs ng/ml) BGP concentrations in dialysate were undetectable in five patients and 34 ng/ml in another patient Plasma BGP levels drawn prospectively in six patients before and after dialysis did not change significantly during 7 to 9 months rrelations between plasma BGP and serum biochemistry There were no correlations between plasma concentrations of BGP and serum levels of calcium, phosphate, and creatinine However, plasma BGP correlated well with serum alkaline phosphatase (r = 85; P < 1) and to a lesser degree with PTH (r = 64; P < 1) rrelations between hone histology, plasma BGP, and serum biochemistry Cancellous bone mass correlated neither with plasma BGP, serum alkaline phosphatase, or PTH Vol ume of lamellar osteoid correlated inversely with BGP but not with alkaline phosphatase or serum PTH There was a direct correlation between volume of woven osteoid, BGP, and PTH The surface of lamellar osteoid correlated negatively with BGP (Fig 2A) and to a lesser degree with alkaline phosphatase and PTH The surface of woven osteoid correlated positively with BGP (Fig 2B) and, again, to a lesser degree with alkaline phosphatase and PTH Other osteoblastic parameters such as bone-osteoblast interface, osteoblastic index, and peritrabecular fibrosis (Fig 3) were also best correlated with plasma BGP and less with alkaline phosphatase and PTH Boneosteoclast interface and osteoclastic index correlated equally with BGP, alkaline phosphatase, and PTH However, these correlations were weaker than those between osteoblastic parameters and BGP Mineral apposition rate correlated well with BGP (Fig 4) and PTH and somewhat less with alkaline phosphatase, whereas actively mineralizing osteoid seams correlated with PTH only Mineralization lag time did not correlate with BGP, alkaline phosphatase, or PTH Discussion The observed correlations between BGP and histomorphometric parameters of bone indicate that BGP is a good marker for osteoblastic activity, in particular for bone matrix and collagen fiber production This is evidenced by a strong correlation between BGP and the volume of woven osteoid, the surface of woven osteoid, and peritrabecular fibrosis The negative correlation between BGP and volume and surface of lamellar osteoid might reflect that, in uremic osteodystrophy, the appearance of woven osteoid is associated with less lamellar osteoid [171 The good correlations between BGP and the number of osteoblasts, bone-osteoblast interface, and mineral apposition rate further support the notion that BGP is an indicator of osteoblastic activity Osteoblastic activity encompasses bone formation and mineralization The lack of correlations between BGP and parameters of bone mineralization, such as fractional labelling of osteoid and mineralization lag time, indicates that BGP reflects mainly bone formation activity by osteoblasts and not bone mineralization in our uremic patients It is of note that BGP levels correlate only marginally with the extent of active resorption lacunae per trabecular surface and

5 Plasma BGP levels reflect bone formation 873 ) ) y = = BGP 35 x 1 (BGP) Plasma levels of BGP, np/rn! Fig 3 rrelation between plasma levels of bone Glaprotein and peritrabecular fibrosis in patients with low bone turnover and osteomalacia () and with high bone turnover and hyperparathyroid bone disease ( ) V = 298 r = BGP 6 x io (BGP) Plasma levels of BGP, np/rn! Fig 4 rrelation between plasma levels of hone Gb-protein and mineral apposition rate in patients with low bone turnover and osteomalacia () and with high bone turnover and hyperparathyrqjd bone disease ( ) the number of osteoclasts per trabecular surface This correlation might be spurious, reflecting the known coupling between bone formation and resorption [181 Our results point to the osteoblasts as the mostlikely site of BGP production This notion agrees with the observation that plasma BGP arises from synthesis of BGP in bone and not from release of BGP through bone resorption [8] In addition, it is in keeping with the finding that BGP is secreted in vitro by osteosarcoma cells which have a PTH responsiveness and alkaline phosphatase activity akin to osteoblasts [19] Our data agree with reports by Delmas et al [6] who found a correlation between plasma BGP levels and bone turnover in osteoporotic patients However, the prevailing notion that BGP is involved in mineralization cannot be confirmed by our results The apparent discrepancy can be explained by the fact that studies ascribing a role fo BGP in mineralization were done either in vitro [2, 211 or in growing rats [22, 231 Our studies were done in patients with various levels of elevated BGP The finding that BGP correlates better with histomorphometric parameters of bone formation than alkaline phosphatase or PTH ascribes a promising role to BGP as a non-invasive tool for assessment of underlying histology This potential is further increased by the fact that BGP, unlike alkaline phosphatase, is a bone-specific protein, that is, not produced by other organs Acknowledgments This study was presented in part at the XVth Annual Meeting of the American ociety of Nephrology, Chicago, 1982, and supported in part by a grant from Dialysis Clinics, Inc (# 129) We thank R Wheaton for skillful technical assistance, and Drs C Wood and R Kryscio, Department of Biostatistics, University of Kentucky, for help in biostatistical evaluation of the data Reprint requests to Dr H H Malluche, Division of Nephrology, Bone and Mineral Metabolism, Department of Medicine, University of Kentucky Medical Center, Lexington, Kentucky , UA References 1 HAUCHKA PV, LIAN J13, GALLO PM: Direct identification of the calcium binding amino acid-carboxyglutamate in mineralized tissue Proc Nail Acad ci LIA 72: , PRICE PA, OTUKA A, POER JW, KRITAPONI J, RAMIN N: Characterization of a 'y-carboxyglutamic acid containing protein from bone Proc Nat! Acad ci UA 73: , PRICE PA, NIHIMOTO K: Radioimmunoassay for thç vitamin K-dependent protein of bone and its discovery in plasma Proc NatI Acad ci UA 77: , DEFTO U, PARTHEMORE JG, PRICE PA: Changes in plasma bone Gla-protein during treatment of bone disease Calcif Tissue mt 34: , jovw DM, GUNDBERG OM, LIAN JB, NEER RM: Clinical evaluation of bone turnover by serum osteocalcin measurements (abstract) Ca/c,f Tissue mt 34:15, DELMA PD, WAHNER HW, MANN KG, RIGG BL: Assessment of bone turnover in postmenopausal osteoporosis by measurement of serum bone Gla-Protein J Lab Clin Med 12:47 476, DELMA PD, WILON DM, MANN KG, RIGG BL: Effect of renal function on plasma levels of bone Gla-protein J C/in Endocrinol Metab 57:128 13, PiucE PA, WILLIAMON MK, LOTI-IRINGER JW- Origin of the vitamin K-dependent bone protein found in plasma and its clearance by kidney and bone J Biol Chem 256: , CHEUNG AK, MANOLAGA5 C, CATHERWOOD BD, MO5ELY CA, MITA JA, BLANTZ RC, DEFTO U: Determinants of serum l,25(oh)2d levels in renal disease, Kidney bit 24:14 19, MALLUCHE HH: The value of bone biopsies for diagnosis of renal bone disease, in Dialysis Transplantation, Nephrology, edited by

6 874 Malluche et al MOORHEAD JR, BAILLOD PA, MION C, London, Pitman Medical, 1973, pp GOLDNER J: A modification of the Masson trichrome technique for routine laboratory purposes A,n J Pathol 14: , MALLUCHE HH, MEYER W, HERMAND, MARY G: Quantitative bone histology in 84 normal American subjects Micromorphometric analysis and evaluation of variance of iliac crest bone Calcif Tissue mt 34: , LILLIE PD, FULLMER HM: Histopathologic Technique and Practical Histochemistry (4th ed), New York, McGraw Hill, 1976, pp MALLUCFIE HH, HERMAN D, MEYER W, MANAKA R, MARY G: A new semiautomatic method for quantitative static and dynamic bone histology Calcif Tissue mt 34: , EGRE GV: Amino-terminal radioimmunoassays for human parathyroid hormone, in Clinical Disorders of Bone and Mineral Metabolism (International ngress eries 617), edited by FRAME B, POTT it, Amsterdam, Oxford, Princeton, Excerpta Medic 1983, pp BARR AG, GOODNIGHT GH, ALL GP, HELWIG GP: A User's Guide, Raleigh, A Institute Inc, 1979, pp MALLUCHE HH, FAUGERE MC: Histopathology of bane, in Renal Osteodvstrophy, edited by COBURN JW, CATTO GRD, Hingham, Martinus Nijhoff, in press 18 FARLEY JR, BAYLINK DJ: Purification of a skeletal growth factor from human bone Biochemistry 21: , NIHIMOTO K, PRICE PA: ecretion of Vitamin K-dependent protein of bone by rat osteosarcoma cells J Biol Chem 255: , PRICE PA, OTUKA A, POER JW, KRITAPNIs J, RAMAN N: Characterization of a y-carboxyglutamic acid-containing protein from bone Proc Nail Acad ci UA 73: , POER JW, PRICE PA: A method for decarboxylation of y-carboxyglutamic acid in proteins JBiol Chem 254: , PRICE PA, WILLIAMsON MK, HABA T, DELL RB, JEE W: Excessive mineralization with growth plate closure in rats on chronic warfarin Proc NatI Acad ci UA 79: , HAUCHKA PV, REDDI AH: rrelation of the appearance of y-carboxyglutamic acid with the onset of mineralization in developing endochondral bone Biochem Biophys Res mmun 92: , 198

Differences in bone turnover and intact PTH levels between African American and Caucasian patients with end-stage renal disease

Differences in bone turnover and intact PTH levels between African American and Caucasian patients with end-stage renal disease Kidney International, Vol. 64 (2003), pp. 737 742 Differences in bone turnover and intact PTH levels between African American and Caucasian patients with end-stage renal disease B. PETER SAWAYA, REZKALLA

More information

Kobe University Repository : Kernel

Kobe University Repository : Kernel Title Author(s) Citation Issue date 2009-09 Resource Type Resource Version DOI URL Kobe University Repository : Kernel Marked increase in bone formation markers after cinacalcet treatment by mechanisms

More information

Renal bone disease 1990: An unmet challenge for the nephrologist

Renal bone disease 1990: An unmet challenge for the nephrologist Kidney International, Vol. 38 (1990), pp. 193 2 11 Renal bone disease 1990: An unmet challenge for the nephrologist EDITORIAL REVIEW The replacement of excretory kidney function by dialysis or by renal

More information

Glycaemic control and serum intact parathyroid hormone levels in diabetic patients on haemodialysis therapy

Glycaemic control and serum intact parathyroid hormone levels in diabetic patients on haemodialysis therapy Nephrol Dial Transplant (2008) 23: 315 320 doi: 10.1093/ndt/gfm639 Advance Access publication 23 October 2007 Original Article Glycaemic control and serum intact parathyroid hormone levels in diabetic

More information

Advances in Peritoneal Dialysis, Vol. 22, 2006

Advances in Peritoneal Dialysis, Vol. 22, 2006 Advances in Peritoneal Dialysis, Vol. 22, 2006 M. Carmen Sánchez González, 1 Fernando López Barea, 2 M. Auxiliadora Bajo, 1 Rafael Selgas, 1 for the Collaborators of the Multicenter Study Group* Serum

More information

OSTEOMALACIA UPDATE. Nothing to Disclose. Daniel D Bikle, MD, PhD Professor of Medicine University of California and VA Medical Center San Francisco

OSTEOMALACIA UPDATE. Nothing to Disclose. Daniel D Bikle, MD, PhD Professor of Medicine University of California and VA Medical Center San Francisco OSTEOMALACIA UPDATE Daniel D Bikle, MD, PhD Professor of Medicine University of California and VA Medical Center San Francisco Nothing to Disclose 1 Case History 59 YO WM referred for evaluation of diffuse

More information

Changes in serum osteocalcin levels in the follow-up of kidney transplantation

Changes in serum osteocalcin levels in the follow-up of kidney transplantation Original Article Ann Clin Biochem 1997; 34: 651--655 Changes in serum osteocalcin levels in the follow-up of kidney transplantation M R Bonnin", M T Gonzalez-, J M GriIi6 2, J M Cruzado", J Bover-, J M

More information

Bone histologic response to deferoxamine in aluminum related bone disease

Bone histologic response to deferoxamine in aluminum related bone disease Kidney International, Vol. 31 (1987), pp. 1344 135 CLINICAL INVESTIGATION Bone histologic response to deferoxamine in aluminum related bone disease DENNIS L. ANDRESS, HENRY G. NEBEKER, SUSAN M. OTT, DAVID

More information

PART FOUR. Metabolism and Nutrition

PART FOUR. Metabolism and Nutrition PART FOUR Metabolism and Nutrition Advances in Peritoneal Dialysis, Vol. 23, 2007 Alicja E. Grzegorzewska, Monika Mĺot Michalska Serum Level of Intact Parathyroid Hormone and Other Markers of Bone Metabolism

More information

Frequency of Metabolic Bone Disease in Haemodialysis Patients

Frequency of Metabolic Bone Disease in Haemodialysis Patients Frequency of Metabolic Bone Disease in Haemodialysis Patients Pages with reference to book, From 83 To 86 Rizwan Hussain, Arshad Ahmed, Abdul Salam Soomro, Saeed Hassan Chishty, Syed Ali Jaffar Naqvi (

More information

Effects of Diabetes Mellitus, Age, and Duration of Dialysis on Parathormone in Chronic Hemodialysis Patients. Hamid Nasri 1, Soleiman Kheiri 2

Effects of Diabetes Mellitus, Age, and Duration of Dialysis on Parathormone in Chronic Hemodialysis Patients. Hamid Nasri 1, Soleiman Kheiri 2 Saudi J Kidney Dis Transplant 2008;19(4):608-613 2008 Saudi Center for Organ Transplantation Saudi Journal of Kidney Diseases and Transplantation Original Article Effects of Diabetes Mellitus, Age, and

More information

DEGREE (if applicable)

DEGREE (if applicable) OMB No. 0925-0001 and 0925-0002 (Rev. 10/15 Approved Through 10/31/2018) BIOGRAPHICAL SKETCH DO NOT EXCEED FIVE PAGES. NAME: Malluche, Hartmut H. era COMMONS USER NAME (credential, e.g., agency login):

More information

K/DOQI-recommended intact PTH levels do not prevent low-turnover bone disease in hemodialysis patients

K/DOQI-recommended intact PTH levels do not prevent low-turnover bone disease in hemodialysis patients http://www.kidney-international.org & 2008 International Society of Nephrology original article see commentary on page 674 K/DOQI-recommended intact PTH levels do not prevent low-turnover bone disease

More information

Hyperparathyroidism and in Malignant Hypercalcemia Comparison with Bone Histomorphometry

Hyperparathyroidism and in Malignant Hypercalcemia Comparison with Bone Histomorphometry Serum Bone Gamma Carboxyglutamic Acid-containing Protein in Primary Hyperparathyroidism and in Malignant Hypercalcemia Comparison with Bone Histomorphometry P. D. Delmas, B. Demiaux, L. Malaval, M. C.

More information

Metabolic Bone Disease (Past, Present and Future Challenges in the Management)

Metabolic Bone Disease (Past, Present and Future Challenges in the Management) Metabolic Bone Disease 871 151 Metabolic Bone Disease (Past, Present and Future Challenges in the Management) SNA RIZVI INTRODUCTION The past 40 years have seen some important historical events leading

More information

PART FOUR. Metabolism and Nutrition

PART FOUR. Metabolism and Nutrition PART FOUR Metabolism and Nutrition Advances in Peritoneal Dialysis, Vol. 21, 2005 Maria Mesquita, 1 Eric Wittersheim, 2 Anne Demulder, 2 Max Dratwa, 1 Pierre Bergmann 3 Bone Cytokines and Renal Osteodystrophy

More information

The Role of the Laboratory in Metabolic Bone Disease

The Role of the Laboratory in Metabolic Bone Disease The Role of the Laboratory in Metabolic Bone Disease Howard Morris PhD, FAACB, FFSc(RCPA) President, IFCC Professor of Medical Sciences, University of South Australia, Clinical Scientist, SA Pathology

More information

CKD-Mineral Bone Disorder (MBD) Pathogenesis of Metabolic Bone Disease. Grants: NIH, Abbott, Amgen, OPKO, Shire

CKD-Mineral Bone Disorder (MBD) Pathogenesis of Metabolic Bone Disease. Grants: NIH, Abbott, Amgen, OPKO, Shire Pathogenesis of Metabolic Bone Disease Stuart M. Sprague, D.O. Chief, Division of Nephrology and Hypertension Professor of Medicine NorthShore University HealthSystem University of Chicago Pritzker School

More information

Case 4 Generalised bone pain

Case 4 Generalised bone pain Case 4 Generalised bone pain C A 34- year- old woman presented complaining of multifocal pain in her chest and legs. The pain was intermittent, was aggravated by weight bearing. Initially was alleviated

More information

BMD: A Continuum of Risk WHO Bone Density Criteria

BMD: A Continuum of Risk WHO Bone Density Criteria Pathogenesis of Osteoporosis Osteoporosis Diagnosis: BMD, FRAX and Assessment of Secondary Osteoporosis AGING MENOPAUSE OTHER RISK FACTORS RESORPTION > FORMATION Bone Loss LOW PEAK BONE MASS Steven T Harris

More information

Bone Disorders in CKD

Bone Disorders in CKD Osteoporosis in Dialysis Patients Challenges in Management David M. Klachko MD FACP Professor Emeritus of Medicine University of Missouri-Columbia Bone Disorders in CKD PTH-mediated high-turnover (osteitis

More information

26 black-and-white and 51 color figures with 154 single illustrations, 34 tables, 1986 KARGER

26 black-and-white and 51 color figures with 154 single illustrations, 34 tables, 1986 KARGER Atlas of Mineralized Bone Histology H.H. Malluche M.-C. Faugere Atlas of Mineralized Bone h listol iogy 26 black-and-white and 51 color figures with 154 single illustrations, 34 tables, 1986 KARGER Basel

More information

histomorphometric evidence of osteomalacia after

histomorphometric evidence of osteomalacia after Gut, 198, 21, 624-631 Low serum levels of 1.25-dihydroxyvitamin D and histomorphometric evidence of osteomalacia after jejunoileal bypass for obesity L MOSEKILDE, F MELSEN, I HESSOV, M S CHRISTENSEN, BJ

More information

Improvement of adynamic bone disease after renal transplantation

Improvement of adynamic bone disease after renal transplantation Brazilian Journal of Medical and Biological Research (2006) 39: 31-41 Adynamic bone disease after transplantation ISSN 0100-879X 31 Improvement of adynamic bone disease after renal transplantation K.A.

More information

Incorporating K/DOQI Using a Novel Algorithm Approach: Regina Qu Appelle s Experience

Incorporating K/DOQI Using a Novel Algorithm Approach: Regina Qu Appelle s Experience Incorporating K/DOQI Using a Novel Algorithm Approach: Regina Qu Appelle s Experience Michael Chan, Renal Dietitian Regina Qu Appelle Health Region BC Nephrology Days There is a strong association among

More information

Nuclear Chromatin-concentrated Osteoblasts in Renal Bone Diseases

Nuclear Chromatin-concentrated Osteoblasts in Renal Bone Diseases tap_919 9..13 Therapeutic Apheresis and Dialysis 15(Supplement 1):9 13 doi: 1.1111/j.1744-9987.211.919.x Therapeutic Apheresis and Dialysis 211 International Society for Apheresis Nuclear Chromatin-concentrated

More information

Ca, Mg metabolism, bone diseases. Tamás Kőszegi Pécs University, Department of Laboratory Medicine Pécs, Hungary

Ca, Mg metabolism, bone diseases. Tamás Kőszegi Pécs University, Department of Laboratory Medicine Pécs, Hungary Ca, Mg metabolism, bone diseases Tamás Kőszegi Pécs University, Department of Laboratory Medicine Pécs, Hungary Calcium homeostasis Ca 1000g in adults 99% in bones (extracellular with Mg, P) Plasma/intracellular

More information

Significance of minimodeling in dialysis patients with adynamic bone disease

Significance of minimodeling in dialysis patients with adynamic bone disease Kidney International, Vol. (5), pp. 33 39 DIALYSIS TRANSPLANTATION Significance of minimodeling in dialysis patients with adynamic bone disease YOSHIFUMI UBARA,TETSUO TAGAMI,SYOHEI NAKANISHI, NAOKI SAWA,

More information

Metabolic Bone Disease Related to Chronic Kidney Disease

Metabolic Bone Disease Related to Chronic Kidney Disease Metabolic Bone Disease Related to Chronic Kidney Disease Deborah Sellmeyer, MD Director, Johns Hopkins Metabolic Bone Center Dept of Medicine, Division of Endocrinology Disclosure DSMB member for denosumab

More information

CKD: Bone Mineral Metabolism. Peter Birks, Nephrology Fellow

CKD: Bone Mineral Metabolism. Peter Birks, Nephrology Fellow CKD: Bone Mineral Metabolism Peter Birks, Nephrology Fellow CKD - KDIGO Definition and Classification of CKD CKD: abnormalities of kidney structure/function for > 3 months with health implications 1 marker

More information

Hyperphosphatemia is associated with a

Hyperphosphatemia is associated with a TREATMENT OPTIONS IN THE MANAGEMENT OF PHOSPHATE RETENTION * George A. Porter, MD, FACP, and Hartmut H. Malluche, MD, FACP ABSTRACT Hyperphosphatemia is an independent risk factor for mortality and cardiovascular

More information

Effects of Orchidectomy on Bone Metabolism in Beagle Dogs

Effects of Orchidectomy on Bone Metabolism in Beagle Dogs FULL PAPER Surgery Effects of Orchidectomy on Bone Metabolism in Beagle Dogs Satoshi FUKUDA 1,2) and Haruzo IIDA 2) 1) International Space Radiation Laboratory and 2) Division of Radiotoxicology and Protection,

More information

Regulation of the skeletal mass through the life span

Regulation of the skeletal mass through the life span Regulation of the skeletal mass through the life span Functions of the skeletal system Mechanical protection skull Movement leverage for muscles Mineral metabolism calcium store Erythropoiesis red blood

More information

BONE TISSUE. Dr. Heba Kalbouneh Associate Professor of Anatomy and Histology

BONE TISSUE. Dr. Heba Kalbouneh Associate Professor of Anatomy and Histology BONE TISSUE Dr. Heba Kalbouneh Associate Professor of Anatomy and Histology BONE FUNCTION Support Protection (protect internal organs) Movement (provide leverage system for skeletal muscles, tendons, ligaments

More information

Bone strength is proportional to bone mass, measured with DXA. Bone turnover markers indicate the status of bone quality.

Bone strength is proportional to bone mass, measured with DXA. Bone turnover markers indicate the status of bone quality. Bone strength is proportional to bone mass, measured with DXA Bone quality depend on bone architecture, rate of bone turnover, quality of bone matrix. Bone turnover markers indicate the status of bone

More information

Biochemical markers of renal osteodystrophy in pediatric

Biochemical markers of renal osteodystrophy in pediatric Kidney International, Vol. 45 (1994), pp. 253 258 Biochemical markers of renal osteodystrophy in pediatric patients undergoing CAPD/CCPD ISIDRO B. SALUSKY, JORGE A. RAMIREZ, WILLIAM OPPENHEIM, BARBARA

More information

GUIDELINE 1. EVALUATION OF CALCIUM AND PHOSPHORUS METABOLISM

GUIDELINE 1. EVALUATION OF CALCIUM AND PHOSPHORUS METABOLISM GUIDELINE 1. EVALUATION OF CALCIUM AND PHOSPHORUS METABOLISM 1.1 Serum levels of calcium, phosphorus, alkaline phosphatase, total CO 2, and PTH measured by a first-generation immunometric parathyroid hormone

More information

Parathyroid hormone (serum, plasma)

Parathyroid hormone (serum, plasma) Parathyroid hormone (serum, plasma) 1 Name and description of analyte 1.1 Name of analyte Parathyroid hormone (PTH) 1.2 Alternative names Parathormone 1.3 NMLC code 1.4 Description of analyte PTH is an

More information

Do We Do Too Many Parathyroidectomies in Dialysis? Sagar Nigwekar MD, MMSc Massachusetts General Hospital

Do We Do Too Many Parathyroidectomies in Dialysis? Sagar Nigwekar MD, MMSc Massachusetts General Hospital Do We Do Too Many Parathyroidectomies in Dialysis? Sagar Nigwekar MD, MMSc Massachusetts General Hospital E-mail: snigwekar@mgh.harvard.edu March 13, 2017 Disclosures statement: Consultant: Allena, Becker

More information

Bone histology in young adult osteoporosis

Bone histology in young adult osteoporosis Bone histology in young adult osteoporosis ELLEN HILLS, C R DUNSTAN, S Y P WONG, R A EVANS From the Metabolic Unit, Concord Hospital, Sydney, Australia J Clin Pathol 1989;42:391-397 SUMMARY Bone histology

More information

Chapter 6: SKELETAL SYSTEM

Chapter 6: SKELETAL SYSTEM Chapter 6: SKELETAL SYSTEM I. FUNCTIONS A. Support B. Protection C. Movement D. Mineral storage E. Lipid storage (Fig. 6.8b) F. Blood cell production (Fig. 6.4) II. COMPONENTS A. Cartilage 1. Hyaline 2.

More information

Comparison of Serum Parathyroid Hormone (PTH) Levels in Hemodialysis and Peritoneal Dialysis Patients. Int.J.Curr.Res.Aca.Rev.2016; 4(11):

Comparison of Serum Parathyroid Hormone (PTH) Levels in Hemodialysis and Peritoneal Dialysis Patients. Int.J.Curr.Res.Aca.Rev.2016; 4(11): Comparison of Serum Parathyroid Hormone (PTH) Levels in Hemodialysis and Peritoneal Dialysis Patients Seyed Seifollah Beladi Mousavi 1, Arman Shahriari 2 and Fatemeh Roumi 3 * 1 Department of Nephrology,

More information

Bsml Polymorphism of the Vitamin D Receptor Gene in Hyperparathyroid or Hypoparathyroid Dialysis Patients

Bsml Polymorphism of the Vitamin D Receptor Gene in Hyperparathyroid or Hypoparathyroid Dialysis Patients Clinical Chemistry / BSMI POLYMORPHISM OF THE VITAMIN D RECEPTOR GENE Bsml Polymorphism of the Vitamin D Receptor Gene in Hyperparathyroid or Hypoparathyroid Dialysis Patients Jacopo Tagliabue, MD,1 Marco

More information

The Skeletal Response to Aging: There s No Bones About It!

The Skeletal Response to Aging: There s No Bones About It! The Skeletal Response to Aging: There s No Bones About It! April 7, 2001 Joseph E. Zerwekh, Ph.D. Interrelationship of Intestinal, Skeletal, and Renal Systems to the Overall Maintenance of Normal Calcium

More information

RENAL OSTEODYSTROPHY continues to

RENAL OSTEODYSTROPHY continues to Variant of Adynamic Bone Disease in Hemodialysis Patients: Fact or Fiction? Lillian A. Rocha, MD, Andrea Higa, MD, Fellype C. Barreto, MD, Luciene M. dos Reis, PhD, Vanda Jorgetti, MD, PhD, Sérgio A. Draibe,

More information

Bone Cell Biology. David W. Dempster, PhD. Professor of Clinical Pathology Columbia University. Bone Remodeling

Bone Cell Biology. David W. Dempster, PhD. Professor of Clinical Pathology Columbia University. Bone Remodeling Bone Cell Biology David W. Dempster, PhD Professor of Clinical Pathology Columbia University Bone Remodeling The skeleton, out of site and often out of mind, is a formidable mass of tissue occupying about

More information

Bone Cell Biology. The Remodeling Cycle. Bone Remodeling. Remodeling Maintains Mechanical Strength. David W. Dempster, PhD

Bone Cell Biology. The Remodeling Cycle. Bone Remodeling. Remodeling Maintains Mechanical Strength. David W. Dempster, PhD Bone Remodeling Bone Cell Biology David W. Dempster, PhD Professor of Clinical Pathology Columbia University The skeleton, out of site and often out of mind, is a formidable mass of tissue occupying about

More information

Advances in Peritoneal Dialysis, Vol. 29, 2013

Advances in Peritoneal Dialysis, Vol. 29, 2013 Advances in Peritoneal Dialysis, Vol. 29, 2013 Takeyuki Hiramatsu, 1 Takahiro Hayasaki, 1 Akinori Hobo, 1 Shinji Furuta, 1 Koki Kabu, 2 Yukio Tonozuka, 2 Yoshiyasu Iida 1 Icodextrin Eliminates Phosphate

More information

Cinacalcet treatment in advanced CKD - is it justified?

Cinacalcet treatment in advanced CKD - is it justified? Cinacalcet treatment in advanced CKD - is it justified? Goce Spasovski ERBP Advisory Board member University of Skopje, R. Macedonia TSN Congress October 21, 2017, Antalya Session Objectives From ROD to

More information

For more information about how to cite these materials visit

For more information about how to cite these materials visit Author(s): University of Michigan Medical School, Department of Cell and Developmental Biology License: Unless otherwise noted, the content of this course material is licensed under a Creative Commons

More information

chapter 1 & 2009 KDIGO

chapter 1 & 2009 KDIGO http://www.kidney-international.org chapter 1 & 2009 DIGO Chapter 1: Introduction and definition of CD MBD and the development of the guideline statements idney International (2009) 76 (Suppl 113), S3

More information

NIH Public Access Author Manuscript Am J Kidney Dis. Author manuscript; available in PMC 2011 May 1.

NIH Public Access Author Manuscript Am J Kidney Dis. Author manuscript; available in PMC 2011 May 1. NIH Public Access Author Manuscript Published in final edited form as: Am J Kidney Dis. 2010 May ; 55(5): 897 906. doi:10.1053/j.ajkd.2009.12.041. Intact PTH Combined With the PTH Ratio for Diagnosis of

More information

BONE HISTOLOGY SLIDE PRESENTATION

BONE HISTOLOGY SLIDE PRESENTATION BONE HISTOLOGY SLIDE PRESENTATION PRESENTED BY: SKELETECH, INC. Clients and Friends: SkeleTech invites you to use these complimentary images for your own presentations or as teaching slides for bone biology.

More information

Skeletal Manifestations

Skeletal Manifestations Skeletal Manifestations of Metabolic Bone Disease Mishaela R. Rubin, MD February 21, 2008 The Three Ages of Women Gustav Klimt 1905 1 Lecture Outline Osteoporosis epidemiology diagnosis secondary causes

More information

Elecsys bone marker panel. Optimal patient management starts in the laboratory

Elecsys bone marker panel. Optimal patient management starts in the laboratory bone marker panel Optimal patient management starts in the laboratory Complete solution for osteoporosis The most complete bone metabolism panel on a single platform bone marker assays are important diagnostic

More information

Ramzi Vareldzis, MD Avanelle Jack, MD Dept of Internal Medicine Section of Nephrology and Hypertension LSU Health New Orleans September 13, 2016

Ramzi Vareldzis, MD Avanelle Jack, MD Dept of Internal Medicine Section of Nephrology and Hypertension LSU Health New Orleans September 13, 2016 Ramzi Vareldzis, MD Avanelle Jack, MD Dept of Internal Medicine Section of Nephrology and Hypertension LSU Health New Orleans September 13, 2016 1 MBD + CKD in Elderly patients Our focus for today: CKD

More information

Effects of Whole Body Exposure to Electromagnetic Field on Normal and Osteoporotic Bone Metabolism in Rats

Effects of Whole Body Exposure to Electromagnetic Field on Normal and Osteoporotic Bone Metabolism in Rats Effects of Whole Body Exposure to tromagnetic Field on Normal and Osteoporotic Bone Metabolism in Rats S. Fukuda and H. Iida National Institute of Radiological Sciences, Chiba 263-8 Japan INTRODUCTION

More information

Renal Osteodystrophy: -Heremans Schmid Glycoprotein/Fetuin-A, Matrix GLA Protein Serum Levels, and Bone Histomorphometry

Renal Osteodystrophy: -Heremans Schmid Glycoprotein/Fetuin-A, Matrix GLA Protein Serum Levels, and Bone Histomorphometry Renal Osteodystrophy: -Heremans Schmid Glycoprotein/Fetuin-A, Matrix GLA Protein Serum Levels, and Bone Histomorphometry Giorgio Coen, MD, Paola Ballanti, PhD, Alessandro Balducci, MD, Fabio Grandi, PhD,

More information

Origin of the Vitamin K-dependent Bone Protein Found in Plasma and

Origin of the Vitamin K-dependent Bone Protein Found in Plasma and THE JOURNAL OF BIOLOGICAL CHEMISTRY Vol. 256, No. 24. Issue of December 25, pp. 12760-12766. 1981 Printed in 11. S. A. Origin of the Vitamin K-dependent Bone Protein Found in Plasma and Its Clearance by

More information

Reversal of adynamic bone disease by lowering of dialysate calcium

Reversal of adynamic bone disease by lowering of dialysate calcium http://www.kidney-international.org & 26 International Society of Nephrology original article Reversal of adynamic bone disease by lowering of dialysate calcium A Haris 1, DJ Sherrard 2 and G Hercz 3 1

More information

Secondary Hyperparathyroidism: Where are we now?

Secondary Hyperparathyroidism: Where are we now? Secondary Hyperparathyroidism: Where are we now? Dylan M. Barth, Pharm.D. PGY-1 Pharmacy Resident Mayo Clinic 2017 MFMER slide-1 Objectives Identify risk factors for the development of complications caused

More information

CONCORD INTERNAL MEDICINE VITAMIN D/CALCIUM/MAGNESIUM PROTOCOL. Revised April 8, 2012

CONCORD INTERNAL MEDICINE VITAMIN D/CALCIUM/MAGNESIUM PROTOCOL. Revised April 8, 2012 CONCORD INTERNAL MEDICINE VITAMIN D/CALCIUM/MAGNESIUM PROTOCOL Douglas G. Kelling, Jr., ND C. Gismondi-Eagan, MD, FACP George C. Monroe, III, MD Revised April 8, 2012 The information contained in this

More information

Renal Osteodystrophy in Pediatric Patients on Peritoneal Dialysis

Renal Osteodystrophy in Pediatric Patients on Peritoneal Dialysis Advances in Peritoneal Dialysis, Vol. 20, 2004 Francisco J. Cano, Marcela Valenzuela, Pedro Zambrano, Marta A. Azocar, Eduardo Wolff, Maria A. Delucchi, Eugenio E. Rodriguez Renal Osteodystrophy in Pediatric

More information

A clinical assessment of the relationship between bone scintigraphy and serum biochemical markers in hemodialysis patients

A clinical assessment of the relationship between bone scintigraphy and serum biochemical markers in hemodialysis patients ORIGINAL ARTICLE Annals of Nuclear Medicine Vol. 18, No. 6, 513 518, 2004 A clinical assessment of the relationship between bone scintigraphy and serum biochemical markers in hemodialysis patients Seiji

More information

Level 1 Strong We recommendyshould A High Moderate Level 2 Weak We suggestymight C Low Very low. K Hyperphosphatemia has been associated with poor

Level 1 Strong We recommendyshould A High Moderate Level 2 Weak We suggestymight C Low Very low. K Hyperphosphatemia has been associated with poor chapter 4.1 http://www.kidney-international.org & 2009 KDIGO Chapter 4.1: Treatment of CKD MBD targeted at lowering high serum phosphorus and maintaining serum calcium ; doi:10.1038/ki.2009.192 Grade for

More information

CKD-MBD CKD mineral bone disorder

CKD-MBD CKD mineral bone disorder CKD Renal bone disease Dr Mike Stone University Hospital Llandough Affects 5 10 % of population Increasingly common Ageing, diabetes, undetected hypertension Associated with: Cardiovascular disease Premature

More information

THE EFFECT OF VARIOUS PATHOLOGIES ON BONE QUALITY

THE EFFECT OF VARIOUS PATHOLOGIES ON BONE QUALITY University of Kentucky UKnowledge Theses and Dissertations--Biomedical Engineering Biomedical Engineering 2014 THE EFFECT OF VARIOUS PATHOLOGIES ON BONE QUALITY Daniel S. Porter University of Kentucky,

More information

FOCUS ON CARDIOVASCULAR DISEASE

FOCUS ON CARDIOVASCULAR DISEASE The Consequences of Vitamin D Deficiency: FOCUS ON CARDIOVASCULAR DISEASE Vitamin D deficiency is a global health problem. With all the medical advances of the century, vitamin D deficiency is still epidemic.

More information

JOURNAL OF INTERNATIONAL ACADEMIC RESEARCH FOR MULTIDISCIPLINARY Impact Factor 1.393, ISSN: , Volume 2, Issue 7, August 2014

JOURNAL OF INTERNATIONAL ACADEMIC RESEARCH FOR MULTIDISCIPLINARY Impact Factor 1.393, ISSN: , Volume 2, Issue 7, August 2014 HYPOVITAMINOSIS D IN INDIAN FEMALES WITH POSTMENOPAUSAL OSTEOPOROSIS DR. SHAH WALIULLAH 1 DR. VINEET SHARMA 2 DR. R N SRIVASTAVA 3 DR. YASHODHARA PRADEEP 4 DR. A A MAHDI 5 DR. SANTOSH KUMAR 6 1 Research

More information

Marie-Claude Monier-Faugere, Hanna Mawad, and Hartmut H. Malluche

Marie-Claude Monier-Faugere, Hanna Mawad, and Hartmut H. Malluche Opposite Effects of Calcitriol and Paricalcitol on the Parathyroid Hormone-(1-84)/Large Carboxy-Terminal- Parathyroid Hormone Fragments Ratio in Patients with Stage 5 Chronic Kidney Disease Marie-Claude

More information

Chapter 5: Evaluation and treatment of kidney transplant bone disease Kidney International (2009) 76 (Suppl 113), S100 S110; doi: /ki.2009.

Chapter 5: Evaluation and treatment of kidney transplant bone disease Kidney International (2009) 76 (Suppl 113), S100 S110; doi: /ki.2009. http://www.kidney-international.org & 2009 KDIGO Chapter 5: Evaluation and treatment of kidney transplant bone disease ; doi:10.1038/ki.2009.193 Grade for strength of recommendation a Strength Wording

More information

Introduction/objective: Adinamic bone disease (ABD) is a common finding in peritoneal. dialysis (PD) and is associated with a

Introduction/objective: Adinamic bone disease (ABD) is a common finding in peritoneal. dialysis (PD) and is associated with a Original Article Low-calcium peritoneal dialysis solution is effective in bringing PTH levels to the range recommended by current guidelines in patients with PTH levels < 150 pg/dl Authors Thyago Proença

More information

Calcitriol, Parathyroid Hormone, and Accumulation of Aluminum

Calcitriol, Parathyroid Hormone, and Accumulation of Aluminum Calcitriol, Parathyroid Hormone, and Accumulation of Aluminum in Bone in Dogs with Renal Failure Hartmut H. Malluche, Marieaude Faugere, Robert M. Friedler, ifford Matthews, and Paolo Fanti Division ofnephrology,

More information

Histomorphometric Analysis of a Non-decalcified Bone Sample (for Non-complex Diseases and for Complex OM-, ROD-, and HPTH-type Diseases)

Histomorphometric Analysis of a Non-decalcified Bone Sample (for Non-complex Diseases and for Complex OM-, ROD-, and HPTH-type Diseases) Histomorphometric Analysis of a Non-decalcified Bone Sample (for Non-complex Diseases and for Complex OM-, ROD-, and HPTH-type Diseases) April 2013 DISCLAIMER: This document was originally drafted in French

More information

Drugs Affecting Bone. Rosa McCarty PhD. Department of Pharmacology & Therapeutics

Drugs Affecting Bone. Rosa McCarty PhD. Department of Pharmacology & Therapeutics Drugs Affecting Bone Rosa McCarty PhD Department of Pharmacology & Therapeutics rmccarty@unimelb.edu.au Objectives At the end of this lecture you should have gained: An understanding of bone metabolism

More information

Bone and Mineral. Comprehensive Menu for the Management of Bone and Mineral Related Diseases

Bone and Mineral. Comprehensive Menu for the Management of Bone and Mineral Related Diseases Bone and Mineral Comprehensive Menu for the Management of Bone and Mineral Related Diseases Innovation to Assist in Clinical Diagnosis and Treatment DiaSorin offers a specialty line of Bone and Mineral

More information

Renal osteodystrophy

Renal osteodystrophy Kidney International, Vol. 17 (1980), pp. 677-693 NEPHROLOGY FORUM Renal osteodystrophy Principal Discussant. JACK W. COBURN Nephrology Section, VA Wadsworth Medical Center and UCLA School of Medicine,

More information

Chapter 6: Skeletal System: Bones and Bone Tissue

Chapter 6: Skeletal System: Bones and Bone Tissue Chapter 6: Skeletal System: Bones and Bone Tissue I. Functions A. List and describe the five major functions of the skeletal system: 1. 2. 3.. 4. 5.. II. Cartilage A. What do chondroblasts do? B. When

More information

Sensipar. Sensipar (cinacalcet) Description

Sensipar. Sensipar (cinacalcet) Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.30.46 Subject: Sensipar Page: 1 of 5 Last Review Date: June 22, 2018 Sensipar Description Sensipar (cinacalcet)

More information

Product: Denosumab (AMG 162) Clinical Study Report: month Primary Analysis Date: 21 November 2016 Page 1

Product: Denosumab (AMG 162) Clinical Study Report: month Primary Analysis Date: 21 November 2016 Page 1 Date: 21 November 2016 Page 1 2. SYNOPSIS Name of Sponsor: Amgen Inc., Thousand Oaks, CA, USA Name of Finished Product: Prolia Name of Active Ingredient: denosumab Title of Study: Randomized, Double-blind,

More information

Peggers Super Summaries Basic Sciences Bone

Peggers Super Summaries Basic Sciences Bone Bone Overview & Turnover BONES Function o Support o Protection o Assisting movement o Storage of minerals o Production of red blood cells from marrow Types o Cancellous o Compact with Haversian systems

More information

2.0 Synopsis. Paricalcitol Capsules M Clinical Study Report R&D/15/0380. (For National Authority Use Only)

2.0 Synopsis. Paricalcitol Capsules M Clinical Study Report R&D/15/0380. (For National Authority Use Only) 2.0 Synopsis AbbVie Inc. Name of Study Drug: ABT-358/Zemplar (paricalcitol) Capsules Name of Active Ingredient: paricalcitol Individual Study Table Referring to Part of Dossier: Volume: Page: (For National

More information

hypercalcemia of malignancy hyperparathyroidism PHPT the most common cause of hypercalcemia in the outpatient setting the second most common cause

hypercalcemia of malignancy hyperparathyroidism PHPT the most common cause of hypercalcemia in the outpatient setting the second most common cause hyperparathyroidism A 68-year-old woman with documented osteoporosis has blood tests showing elevated serum calcium and parathyroid hormone (PTH) levels: 11.2 mg/dl (8.8 10.1 mg/dl) and 88 pg/ml (10-60),

More information

NATIONAL QUALITY FORUM Renal EM Submitted Measures

NATIONAL QUALITY FORUM Renal EM Submitted Measures NATIONAL QUALITY FORUM Renal EM Submitted Measures Measure ID/ Title Measure Description Measure Steward Topic Area #1662 Percentage of patients aged 18 years and older with a diagnosis of CKD ACE/ARB

More information

Vascular calcification in stage 5 Chronic Kidney Disease patients on dialysis

Vascular calcification in stage 5 Chronic Kidney Disease patients on dialysis Vascular calcification in stage 5 Chronic Kidney Disease patients on dialysis Seoung Woo Lee Div. Of Nephrology and Hypertension, Dept. of Internal Medicine, Inha Unv. College of Medicine, Inchon, Korea

More information

Module 2:! Functional Musculoskeletal Anatomy A! Semester 1! !!! !!!! Hard Tissues, Distal Upper Limb & Neurovascular Supply of Upper Limb!

Module 2:! Functional Musculoskeletal Anatomy A! Semester 1! !!! !!!! Hard Tissues, Distal Upper Limb & Neurovascular Supply of Upper Limb! Functional Musculoskeletal Anatomy A Module 2: Hard Tissues, Distal Upper Limb & Neurovascular Supply of Upper Limb Semester 1 1 18. Bone Tissue & Growth of Bones 18.1 Describe the structure of bone tissue

More information

Profile of mineral bone disease in Pre-dialytic stage 3-5 Chronic Kidney Disease Patients: A Cross-Sectional Study

Profile of mineral bone disease in Pre-dialytic stage 3-5 Chronic Kidney Disease Patients: A Cross-Sectional Study Profile of mineral bone disease in Pre-dialytic stage 3-5 Chronic Kidney Disease Patients: A Cross-Sectional Study Balaraman Velayudham 1, Praveen Balaguru 2, Nagendran Vijayakumar 3, Shankar.P 4 1,3,4-Dept.

More information

Setting the standard

Setting the standard SCLEROSTIN in NEPHROLOGY MOST REFERENCED OPTIMIZED FOR CLINICAL SAMPLES Setting the standard for clinical research. SCLEROSTIN A BONE-RELATED PROTEIN URINE PROTOCOL AVAILABLE Sclerostin ELISA - Assay Characteristics

More information

The relief of bone pain in primary biliary cirrhosis with calcium infusions

The relief of bone pain in primary biliary cirrhosis with calcium infusions Gut, 1974, 15, 788-793 The relief of bone pain in primary biliary cirrhosis with calcium infusions A. B. AJDUKIEWICZ, J. E. AGNEW, P. D. BYERS, M. R. WILLS1, AND SHEILA SHERLOCK From the Departments of

More information

THE NEW ZEALAND MEDICAL JOURNAL

THE NEW ZEALAND MEDICAL JOURNAL THE NEW ZEALAND MEDICAL JOURNAL Vol 116 No 1179 ISSN 1175 8716 Efficacy of an oral, 10-day course of high-dose calciferol in correcting vitamin D deficiency Fiona Wu, Toni Staykova, Anne Horne, Judy Clearwater,

More information

Awaisheh. Mousa Al-Abbadi. Abdullah Alaraj. 1 Page

Awaisheh. Mousa Al-Abbadi. Abdullah Alaraj. 1 Page f #3 Awaisheh Abdullah Alaraj Mousa Al-Abbadi 1 Page *This sheet was written from Section 1 s lecture, in the first 10 mins the Dr. repeated all the previous material relating to osteoporosis from the

More information

Biochemistry #01 Bone Formation Dr. Nabil Bashir Farah Banyhany

Biochemistry #01 Bone Formation Dr. Nabil Bashir Farah Banyhany Biochemistry #01 Bone Formation Dr. Nabil Bashir Farah Banyhany Greetings This lecture is quite detailed, but I promise you will make it through, it just requires your 100% FOCUS! Let s begin. Today s

More information

KEY CONCEPTS Unit 6 THE SKELETAL SYSTEM

KEY CONCEPTS Unit 6 THE SKELETAL SYSTEM ANATOMY & PHYSIOLOGY 1 (101-805 - AB) PAUL ANDERSON 2011 KEY CONCEPTS Unit 6 THE SKELETAL SYSTEM A Overview of The Skeletal System 1. Definition: Anatomically the SKELETAL SYSTEM consists of bones, cartilages,

More information

PARATHYROID, VITAMIN D AND BONE

PARATHYROID, VITAMIN D AND BONE PARATHYROID, VITAMIN D AND BONE G M Kellerman Pathology North Hunter Service 30/01/2015 BIOLOGY OF BONE Bone consists of protein, polysaccharide components and mineral matrix. The mineral is hydroxylapatite,

More information

SKELETAL SYSTEM CHAPTER 07. Bone Function BIO 211: ANATOMY & PHYSIOLOGY I. Body Movement interacts with muscles bones act as rigid bar of a lever

SKELETAL SYSTEM CHAPTER 07. Bone Function BIO 211: ANATOMY & PHYSIOLOGY I. Body Movement interacts with muscles bones act as rigid bar of a lever Page 1 BIO 211: ANATOMY & PHYSIOLOGY I 1 CHAPTER 07 SKELETAL SYSTEM Dr. Lawrence G. G. Altman www.lawrencegaltman.com Some illustrations are courtesy of McGraw-Hill. Some illustrations are courtesy of

More information

Osseous Tissue and Bone Structure

Osseous Tissue and Bone Structure C h a p t e r 6 Osseous Tissue and Bone Structure PowerPoint Lecture Slides prepared by Jason LaPres Lone Star College - North Harris Copyright 2009 Pearson Education, Inc., publishing as Pearson Benjamin

More information

BONE REMODELLING. Tim Arnett. University College London. Department of Anatomy and Developmental Biology

BONE REMODELLING. Tim Arnett. University College London. Department of Anatomy and Developmental Biology BONE REMODELLING Tim Arnett Department of Anatomy and Developmental Biology University College London The skeleton, out of sight and often out of mind, is a formidable mass of tissue occupying about 9%

More information

SKELETAL SYSTEM CHAPTER 07 BIO 211: ANATOMY & PHYSIOLOGY I

SKELETAL SYSTEM CHAPTER 07 BIO 211: ANATOMY & PHYSIOLOGY I BIO 211: ANATOMY & PHYSIOLOGY I 1 CHAPTER 07 SKELETAL SYSTEM Dr. Lawrence G. G. Altman www.lawrencegaltman.com Some illustrations are courtesy of McGraw-Hill. Some illustrations are courtesy of McGraw-Hill.

More information

HYDROCHLORIDE FOR THE TREATMENT OF SECONDARY HYPERPARATHYROIDISM IN PATIENTS WITH END-STAGE RENAL DISEASE ON MAINTENANCE DIALYSIS THERAPY

HYDROCHLORIDE FOR THE TREATMENT OF SECONDARY HYPERPARATHYROIDISM IN PATIENTS WITH END-STAGE RENAL DISEASE ON MAINTENANCE DIALYSIS THERAPY UK RENAL PHARMACY GROUP SUBMISSION TO THE NATIONAL INSTITUTE FOR CLINICAL EXCELLENCE on CINACALCET HYDROCHLORIDE FOR THE TREATMENT OF SECONDARY HYPERPARATHYROIDISM IN PATIENTS WITH END-STAGE RENAL DISEASE

More information

The Parathyroid Glands Secrete Parathyroid Hormone, which Regulates Calcium, Magnesium, and Phosphate Ion Levels

The Parathyroid Glands Secrete Parathyroid Hormone, which Regulates Calcium, Magnesium, and Phosphate Ion Levels 17.6 The Parathyroid Glands Secrete Parathyroid Hormone, which Regulates Calcium, Magnesium, and Phosphate Ion Levels Partially embedded in the posterior surface of the lateral lobes of the thyroid gland

More information